Full Press Release Details
HOLON, Israel, Nov. 3, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI, today announced that management will participate in the following upcoming investor conferences in November 2026:
Stifel 2026 Healthcare Conference Date: Tuesday, November 10, 2026 Location: New York, NY Format: Fireside chat and 1x1 meetings Fireside chat time: 11:20 am ET
2026 Jefferies Global Healthcare Conference Date: Wednesday and Thursday, November 18-19, 2026 Location: London, UK Format: 1x1 meetings
Please contact your Stifel or Jefferies representative for additional information or to schedule a meeting with Compugen.
A live webcast of the fireside chat will be available on the events page of the Investor Relations section of Compugen's website at www.cgen.com. A replay will be available following the live event.
About Compugen Compugen is a clinical-stage therapeutic discovery and development company utilizing Unigen™, its AI-powered computational discovery platform, to identify novel drug targets and to develop therapeutics in the field of cancer immunotherapies. Compugen's innovative immuno-oncology pipeline consists of COM701, rilvegostomig and GS-0321 (previously COM503). COM701, a potential first-in-class anti-PVRIG antibody, is currently being evaluated in a blinded randomized ovarian cancer adaptive platform trial as a single agent in maintenance therapy in relapsed platinum sensitive ovarian cancer (named MAIA-ovarian trial). Rilvegostomig, a PD-1/TIGIT bispecific antibody with a TIGIT component that is derived from COM902, Compugen's anti-TIGIT antibody, is being developed by AstraZeneca pursuant to an exclusive license agreement between Compugen and AstraZeneca and is being evaluated in multiple Phase 3, Phase 2 and Phase 1 clinical trials. GS-0321 (previously COM503), Compugen's potential first-in-class high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18, is licensed to Gilead and is being evaluated in a Phase 1 clinical trial that Compugen is conducting. In addition, Compugen has an early-stage immuno-oncology pipeline that consists of research programs aiming to address various mechanisms to enhance anti-cancer immunity. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.